Benzinga | Dec 8, 2021 07:24AM EST

Wells Fargo Initiates Coverage On Kezar Life Sciences with Overweight Rating, Announces Price Target of $19

Wells Fargo analyst Derek Archila initiates coverage on Kezar Life Sciences (NASDAQ:KZR) with a Overweight rating and announces Price Target of $19.